With the ink still drying on a $365 million deal to in-license rights to a therapeutic cancer vaccine and immunotherapy tech at Aduro BioTech, J&J is back with the news that it is also helping to bankroll the company's research work, jumping into a syndicate which has pledged $55 million to fuel an advanced drug study.
AstraZeneca's executive crew extended one of the biggest shopping sprees in the industry with a pact, in-licensing rights to a drug from Synairgen that targets the viral infections that afflict the respiratory tracts of asthma patients. And the little biotech's shares soared on the news.
AbbVie will have exclusive promotion rights to the sole FDA-approved point-of-care test for the hepatitis C virus, under a co-promotion agreement with OraSure Technologies, maker of the OraQuick HCV Rapid Test.
Four pharma service providers, led by MPI Research, have joined forces to form KPI Therapeutics, a new biotech designed to develop promising drug candidates and speed their way to market.
Aprecia has an MIT-licensed method of 3-D printing pills and a plan to hit the market with easy-to-take formulations of top-selling medicines. To get there, the biotech has tapped CRO inVentiv Health, which is on hand to lend its commercialization expertise.
As many drugmakers scale down their R&D presences in India, Bristol-Myers Squibb is strengthening its relationship with Syngene, the CRO arm of local giant Biocon.
The Institute of Cancer Research, London, became the latest member of a consortium seeking to integrate magnetic resonance imaging into radiation therapy.
Roche's Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer.
Deepening its ties with Dutch antibody specialist arGEN-X, Shire has expanded the scope of the pair's R&D agreement and kicked in some cash to get the ball rolling.
A team of biomedical engineers, venture capitalists and device businesspeople are launching a new incubator for med tech startups in Silicon Valley.